Insilico Medicine in the Media

Insilico Medicine’s Alex Zhavoronkov bets China and AI can deliver the drug industry’s next breakthrough

AI drug discovery firm Insilico Medicine is profitable, publicly listed in Hong Kong, and running the drug industry's most consequential experiment.

How Insilico Medicine Is Using AI To Reinvent Drug Discovery

Insilico Medicine has shown that generative AI can dramatically accelerate drug discovery, but its bigger challenge is turning one breakthrough into a repeatable process.

Insilico Medicine advances AI drug for IPF to Phase III trials

Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety evaluations into…

Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.

Insilico Medicine – Weekly Recap

Insilico Medicine Highlights AI-Driven Lab Automation and Digital R&D Transformation

Insilico Medicine Showcases AI-Discovered Inhaled Rentosertib Program at ATS 2026

Insilico Medicine Showcases Antibody Developability Research at PEGS Boston

Insilico Medicine Showcases Antibody Developability Research at PEG Summit

Insilico Medicine Highlights MMAI Gym for AI-Driven Drug Discovery

Insilico Medicine Advances AI Retrosynthesis Benchmarking With ChemCensor Framework

Insilico Medicine Expands MMAI Gym With New AI Benchmark Leaderboards

Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on…

Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine: Report

Lilly ‌will ​acquire ​exclusive ⁠rights to sell a ​GLP-1 drug for diabetes ​from Insilico Medicine, the FT ‌report said, citing sources familiar ​with ​the ⁠matter.

Insilico Medicine advances Middle East push with UAE AI drug discovery deal

Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates’ drug regulator to advance the use of its artificial intelligence tools in drug discovery across the region, even as geopolitical tensions escalate in the Middle East. Shares of Insilico rose as…